EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses

Data Readoutpositivemuscle preserverPositive

AI Analysis

Summary

Regeneron's muscle preserver demonstrated benefit at lower doses in COURAGE data, supporting advancement to a further Phase II trial in older patients.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Showed benefit at lower doses in COURAGE data

Importance:6/10

Sentiment:

0.65

EASD 2026Phase 2 datamuscle preserverlower dose benefitolder patients

Related Companies

$REGN

Read the original article

Published by Clinical Trials Arena on October 2, 2026 10:10 AM

Read Original